CollPlant
-
Biologics
CollPlant Renews Distribution Agreement for Its Soft Tissue Repair Product Vergenix™STR With Arthrex a World Leader in Orthopedics
NESS ZIONA, Israel, March 18, 2019 /PRNewswire/ — CollPlant(NASDAQ: CLGN), a regenerative medicine company, today announced that it has renewed its exclusive distribution agreement with Arthrex for Vergenix™STR for the…
Read More » -
Biologics
CollPlant Receives Research and Development Project Approval From the Israel Innovation Authority to Advance its Collagen-based BioInk for 3D Printing of Tissues and Organs
NESS ZIONA, Israel, June 26, 2018 /PRNewswire/ — CollPlant (NASDAQ: CLGN) (TASE: CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen (recombinant human collagen) technology…
Read More » -
Biologics
CollPlant Opens a New rhCollagen Production Facility
NESS ZIONA, Israel, April 23, 2018 /PRNewswire/ — CollPlant (NASDAQ: CLGN) (TASE:CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products today…
Read More » -
Biologics
CollPlant Announces ADS Listing on NASDAQ
NESS ZIONA, Israel, January 31, 2018 /PRNewswire/ — CollPlant (NASDAQ: CLGN) (TASE: CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair…
Read More » -
Biologics
CollPlant Expands European Sales Network: The Company Has Signed a Distribution Agreement in Greece and Cyprus for Vergenix®FG
NESS ZIONA, Israel, Nov. 28, 2017 /PRNewswire/ — CollPlant (TASE: CLPT, OTC: CQPTY) – a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue…
Read More » -
Financial
CollPlant in Advanced Negotiations for US Private Placement of USD 5.0 million; Agreement Includes Plan for NASDAQ Uplisting
NESS ZIONA, Israel, September 5, 2017 /PRNewswire/ — CollPlant (TASE: CLPT) – a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair…
Read More » -
Biologics
CollPlant Provides Operational Update for Q1 2017
NESS ZIONA, Israel, May 31, 2017 /PRNewswire/ — CollPlant (TASE: CLPT), a regenerative medicine company utilizing its proprietary plant-based rhCollagen…
Read More » -
Biologics
CollPlant Provides Commercial and Operational Update
NESS ZIONA, Israel, March 30, 2017 /PRNewswire CollPlant (TASE: CLPT), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology…
Read More » -
Financial
CollPlant Signs Exclusive Distribution Agreement with Arthrex for Vergenix™STR
NESS ZIONA, Israel, November 8, 2016 /PRNewswire/ — CollPlant Ltd. (TASE: CLPT), a regenerative medicine company utilizing its proprietary plant-based recombinant human collagen (rhCollagen)…
Read More » -
Hospitals
CollPlant Receives CE Mark for Vergenix™STR for Treatment of Tendinopathy
NESS ZIONA, Israel, October 19, 2016 /PRNewswire/ — CollPlant (TASE: CLPT), a regenerative medicine company utilizing its proprietary plant-based rhCollagen (recombinant human collagen) technology…
Read More » -
Hospitals
CollPlant Reports Positive Final Extended Clinical Trial Results with Vergenix™STR for Treatment of Tendinopathy
Ness Ziona, Israel, August 17, 2016 – CollPlant Ltd. (TASE: CLPT), a regenerative medicine company utilizing its proprietary plant-based rhCollagen…
Read More » -
Financial
CollPlant Receives Chief Scientist’s Authorization for a NIS 12 Million Research and Development Projects with Funding of Approximately 50%
NESS ZIONA, Israel, May 31, 2016 /PRNewswire/ — CollPlant Ltd. (TASE: CLPT), a regenerative medicine company utilizing its proprietary plant-based…
Read More » -
Recon
CollPlant Reports Positive Interim Trial Results for Vergenix™STR, Indicated for the Treatment of Tendinopathy
CollPlant Ltd. (TASE:CLPT), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products, today announced positive…
Read More » -
Recon
CollPlant Announces Completion of Patient Recruitment for Clinical Trial of Vergenix™FG (Flowable Gel) for the Treatment of Chronic Wounds
CollPlant Ltd. (TASE:CLPT; OTC:CQPTY), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products, announce that…
Read More » -
Recon
CollPlant Names Shomrat Shurtz Senior Director of Business Development
CollPlant Ltd. (TASE:CLPT; OTC:CQPTY), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products, today announced…
Read More »